Anti-Tac (daclizumab, Zenapax) in the Treatment of Leukemia, Autoimmune Diseases, and in the Prevention of Allograft Rejection: A 25-Year Personal Odyssey

Author： Waldmann Thomas  

Publisher： Springer Publishing Company

ISSN： 0271-9142

Source： Journal of Clinical Immunology, Vol.27, Iss.1, 2007-01, pp. : 1-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effect of daclizumab (Zenapax) on prevention of acute rejection of renal transplantation

By Poorrezagholi F.   Einollahi B.   Firoozan A.   Nafar M.   Yadegari H.   Moghaddam S.M.M.H.   Simforoosh N.   Basiri A.   Farhangi S.  

Transplantation Proceedings, Vol. 35, Iss. 7, 2003-11 ,pp. : 2735-2736

Elsevier

Access to resources Recommend Favorite

Placebo-Controlled Study of a Humanized Anti-TAC Monoclonal Antibody in Dual Therapy for Prevention of Acute Rejection After Renal Transplantation

By Charpentier B.   Thervet E.  

Transplantation Proceedings, Vol. 30, Iss. 4, 1998-06 ,pp. : 1331-1332

Elsevier

Access to resources Recommend Favorite

Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation

By Ekberg H.   Backman L.   Tufveson G.   Tyden G.  

Transplantation Proceedings, Vol. 31, Iss. 1, 1999-02 ,pp. : 267-268

Elsevier

Access to resources Recommend Favorite

Emerging therapeutic strategies for the prevention and treatment of chronic allograft rejection

By Hayry P.   Savolainen H.   Luoto N.M.   Petrov L.   Loubtchenkov M.   Aavik E.  

Transplantation Proceedings, Vol. 32, Iss. 3, 2000-05 ,pp. : 519-519

Elsevier

Access to resources Recommend Favorite

Prevention of chronic heart allograft rejection

By Valantine-von Kaeppler H.A.  

Transplantation Proceedings, Vol. 31, Iss. 1, 1999-02 ,pp. : 1288-1289

Elsevier

Access to resources Recommend Favorite